Shots:

• The P-II (GUARD) trial evaluates Angion’s ANG-3777 vs PBO in a ratio (1:1) in 275 patients at risk for CSA-AKI at 31 centers in the US, Canada, Brazil & Georgia
• The trial failed to meet its 1EP of percentage increase in serum creatinine-based upon AUC & 2EPs of MAKE90 showed potential benefit in patients who received ANG-3777 (14.7% vs 21.5%), patients experienced a decline in kidney function as measured by a >25% decrease in eGFR @90 Day (5.6% vs 16.2%)
• Additionally, other 2EPs did not show a clinical benefit, including EPs on MAKE30 along with the incidence of AKI @6Day while the overall safety profile was consistent with the overall experience in its clinical development program

 Ref: Businesswire | Image: Vifor